In a Phase 1 trial, the investigational glutaminase-1 (GLS1) inhibitor IACS-6274—combined with paclitaxel and bevacizumab—showed tumor shrinkage signals in advanced platinum-resistant ovarian cancer. Across 14 patients, nine of 13 evaluable participants achieved confirmed partial responses while the regimen demonstrated a safety profile consistent with combination therapy tolerability. The findings position GLS1 inhibition as a potential metabolic lever in ovarian cancer by targeting tumor dependence on glutamine metabolism. The study is early and not powered for definitive comparative efficacy, but the response depth and confirmation provide a practical basis for next-stage development. For biotech pipelines, the result strengthens a growing metabolic-immunology playbook: pairing metabolic stressors with standard oncology backbones to overcome resistance.
Get the Daily Brief